AstraZeneca PLC said a late-stage trial of a combination treatment with Imfinzi failed its primary goal of extending the lives of certain lung cancer patients.
The trial, dubbed Neptune, evaluated Imfinzi, or durvalumab, in combination with tremelimumab against standard chemotherapy in patients with previously untreated advanced non-small cell lung cancer and high levels of gene mutations.
The study showed the Imfinzi-tremelimumab combination failed to extend patients' lives compared to platinum-based chemotherapy.
The safety and tolerability profile for the combination of Imfinzi and tremelimumab was consistent with previous trials.
The Cambridge, U.K.-based drugmaker will present the full results of the trial at a forthcoming medical meeting.
Imfinzi belongs to a class of drugs known as immunotherapy, which boost the body's immune system to fight cancer.
